Eli Lilly: Tactical Buy After Another Convincing Quarter - Upgrade to Buy
Eli Lilly's Q1 2026 beat and guidance raise, driven by demand for Mounjaro and Zepbound plus a new oral GLP-1 approval, create a clear short-to-mid-term trading opportunity. Technicals confirm a fresh bullish leg and heavy volume today supports an immediate entry. Valuation is premium, but fundamentals and catalysts justify a measured buy with a de…